MiniMed Group, Inc. 近日宣布，其Simplera Sync™持续葡萄糖监测传感器已获得加拿大卫生部颁发的医疗器械许可证。此次获批的关键意义在于，该传感器可与MiniMed™ 780G先进混合闭环胰岛素输注系统联合使用，并正式扩展适用于2型糖尿病患者群体。
这一监管里程碑标志着Simplera Sync™传感器在加拿大的应用范围得到重要拓宽。此前，该技术主要面向1型糖尿病患者，如今将为更广泛的2型糖尿病群体提供创新的血糖管理解决方案。MiniMed™ 780G系统作为先进的自动化胰岛素输送技术，与传感器的结合将实现更精准、个性化的血糖控制。
此次获批不仅强化了MiniMed在糖尿病管理领域的创新领导者地位，也为加拿大2型糖尿病患者带来了全新的治疗选择。该组合方案旨在通过持续监测和自动胰岛素调节，帮助患者实现更稳定的血糖水平，提升生活质量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.